AstraZeneca will pay up to $420M for Moderna's mRNA technology

Moderna Therapeutics granted AstraZeneca five-year exclusive rights to use its messenger RNA technology to develop and market treatments for cancer and other serious diseases. Moderna will receive $240 million upfront and as much as $180 million in milestone fees plus sales royalties. The deal's initial payment is one of the biggest ever in a pharmaceutical licensing agreement that doesn't involve a clinical-stage drug.

View Full Article in:

New York Times (tiered subscription model), The · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX